OTCMKTS:TEAR

TearLab (TEAR) Stock Forecast, Price & News

$0.06

0.00 (-1.86%)

(As of 07/9/2020)

Compare

Today's Range: $0.06
▼
$0.06
50-Day Range: $0.06
▼
$0.06
52-Week Range: $0.02
▼
$0.22

Volume: 20,200 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest

About TearLab (OTCMKTS:TEAR) Stock

TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.

Receive TEAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TearLab and its competitors with MarketBeat's FREE daily newsletter.

TEAR Stock News Headlines

March 27, 2023 | americanbankingnews.com

Critical Analysis: TearLab (OTCMKTS:TEAR) vs. Treace Medical Concepts (NASDAQ:TMCI)

January 15, 2023 | marketwatch.com

Ocular Allergy Diagnostic Systems Market Size 2023 with End-user Industries, Segments Covered in the Report

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

September 9, 2022 | yahoo.com

Housing Authority officials want more police help at East Acres

September 9, 2022 | yahoo.com

Lawrence schools on 'good footing' financially

September 9, 2022 | nz.finance.yahoo.com

Pathway Makes Four Senior Promotions

September 7, 2022 | apnews.com

TearLab® Announces Corporate Name Change to Trukera™ Medical, Positions Company for Further Expansion in Corneal Health

July 20, 2022 | thestreet.com

Cramer's Top Stock Picks: CLDX OXY TEAR TSLA

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

June 8, 2022 | finance.yahoo.com

Nacuity Pharmaceuticals Strengthens Scientific Advisory Board with Appointment of Nancy Holekamp, M.D., and Richard L. Lindstrom, M.D. - Yahoo Finance

May 23, 2022 | marketscreener.com

AXIM BIOTECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com

May 20, 2022 | marketscreener.com

Greenbrook TMS : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS - Form 6-K - Marketscreener.com

May 12, 2022 | streetinsider.com

Xequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth - StreetInsider.com

May 11, 2022 | benzinga.com

Xequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth - B - Benzinga

May 11, 2022 | globenewswire.com

Xequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth - GlobeNewswire

April 12, 2022 | streetinsider.com

Form DEF 14A LENSAR, Inc. For: May 25 - StreetInsider.com

December 10, 2021 | finance.yahoo.com

TearLab Corporation Announces Adam Szaronos as President and Chief Executive Officer, and Jim Mazzo as Executive Chairman of the Board

November 10, 2021 | markets.businessinsider.com

TearLab Positioned For Growth With Jim Mazzo Joining Board of Directors

November 9, 2021 | prnewswire.com

TearLab Positioned For Growth With Jim Mazzo Joining Board of Directors - PRNewswire

November 3, 2021 | seekingalpha.com

Amgen, Inc. (AMGN) CEO Bob Bradway on Q3 2021 Results - Earnings Call Transcript - Seeking Alpha

October 6, 2021 | streetinsider.com

AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board - StreetInsider.com

October 5, 2021 | finance.yahoo.com

AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board - Yahoo Finance

October 4, 2021 | streetinsider.com

Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan - StreetInsider.com

September 17, 2021 | prnewswire.com

MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans - PRNewswire

June 14, 2021 | streetinsider.com

Accelmed Expands Senior Team With Two New Partners - StreetInsider.com

May 5, 2021 | stockhouse.com

Ceyeber Announces Advisory Board of World-Renowned Ophthalmologists - Stockhouse

April 28, 2021 | ca.finance.yahoo.com

Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

See More Headlines

TEAR Price History

30 days | 90 days | 365 days | Advanced Chart

TEAR Company Calendar

Last Earnings: 8/08/2019
Today: 6/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:TEAR
Previous Symbol: NASDAQ:TEAR
CUSIP: N/A
CIK: 1299139
Web: www.tearlab.com
Phone: 858-455-6006
Fax: 858-812-0540
Employees: 34
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Elias Vamvakas (Age 60)
Exec. Chairman & Sec.

Mr. Joseph S. Jensen (Age 47)
CEO & Director

Mr. Michael Marquez (Age 37)
Chief Financial Officer

Dr. Benjamin Sullivan Ph.D. (Age 43)
Chief Scientific Officer

Mr. Sam Fakhoury
VP of Quality, Compliance & Supply Chain

Key Competitors

View All Competitors

TEAR Stock - Frequently Asked Questions

How have TEAR shares performed in 2023?: TearLab's stock was trading at $0.0579 at the beginning of the year. Since then, TEAR shares have increased by 0.0% and is now trading at $0.0579.
View the best growth stocks for 2023 here.
How were TearLab's earnings last quarter?: TearLab Co. (OTCMKTS:TEAR) released its earnings results on Thursday, August, 8th. The medical research company reported ($0.10) earnings per share for the quarter. The medical research company earned $5.85 million during the quarter.
When did TearLab's stock split?: TearLab shares reverse split on the morning of Friday, February 24th 2017. The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 23rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of TearLab own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TearLab investors own include Vertex Energy (VTNR), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Biocept (BIOC) and MEI Pharma (MEIP).

What is TearLab's stock symbol?: TearLab trades on the OTCMKTS under the ticker symbol "TEAR."
How do I buy shares of TearLab?: Shares of TEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is TearLab's stock price today?: One share of TEAR stock can currently be purchased for approximately $0.06.
How can I contact TearLab?: TearLab's mailing address is 150 La Terraza Blvd. Suite 101, Escondido CA, 92025. The official website for the company is www.tearlab.com. The medical research company can be reached via phone at 858-455-6006, via email at lroth@theruthgroup.com, or via fax at 858-812-0540.

This page (OTCMKTS:TEAR) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial